EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.21.27 | more |
- |
 |
| 3.4.21.27 | more |
inhibition by recombinant Kunitz domain |
|
| 3.4.21.27 | more |
the recombinant catalytic domain Ile370-Val607 of FXIa inhibits the binding of factor XIa to the platelets with a Ki of 3.5 nM, whereas the recombinant factor XI heavy chain does not |
|
| 3.4.21.27 | more |
inhibitor design and synthesis, overview, inhibitor in vitro anticoagulant activity in human plasma |
|
| 3.4.21.27 | more |
heparin accelerates inhibition of factor XIa. Heparin enhances antithrombin inhibition of catalytic domain-wild-type 212fold, but only 37-94fold for catalytic domain mutants |
|
| 3.4.21.27 | more |
potent activated factor VII inhibition with insect-derived serine protease inhibitor, but this protein is only 10fold selective over activated factor X. Inhibition by FXI neutralizing antibodies, which allow preexisting activated factor XI to remain active |
|
| 3.4.21.27 | more |
a monoclonal antibody against FXI or activated factor XI reduces thrombus formation in balloon-injured iliac arteries |
|
| 3.4.21.27 | more |
ketoarginine-based peptidomimetics are irreversible inhibitors of actived factor XI and form a covalent bond to the catalytic serine of the enzyme. Intravenous infusion is efficacious in a rat model of venous thrombosis. A pyridyl analog in a rat mesenteric bleeding model at a 4fold efficacious dose does not alter bleeding time |
|
| 3.4.21.27 | more |
Arg184 may be part of a switch that holds FXI in an inactive conformation in the zymogen |
|
| 3.4.21.27 | more |
not inhibited by protease nexin-2 mutant R15A |
|
